Zhiwei Wu

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Zhiwei Wu, Yaling Hu, Miao Xu et al. · The Lancet Infectious Diseases · 2021 · 575 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

Bihua Han, Yufei Song, Changgui Li et al. · The Lancet Infectious Diseases · 2021 · 355 citations · Full text

Veterinary Medicine, Immunology, Pediatrics +16

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

Gang Zeng, Qianhui Wu, Hongxing Pan et al. · The Lancet Infectious Diseases · 2021 · 287 citations · Full text

Veterinary Medicine, Immunology, Immunization +13

Visualising the expansion and spread of coronavirus disease 2019 by cartograms

Peichao Gao, Hong Zhang, Zhiwei Wu et al. · Environment and Planning A Economy and Space · 2020 · 50 citations · Full text

Social Sciences, Public Health Informatics, Visualization +17

A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Minjie Li, Juan Yang, Lin Wang et al. · medRxiv · 2021 · 37 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17